A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

Authors
Category Primary study
JournalANNALS OF ONCOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 6833b0592009ede81ed2178018853303666bd3b3
First added on: Feb 12, 2025